Cabozantinib, an inhibitor targeting VEGF, MET, and the “anexelekto” receptor tyrosine kinase, was approved by FDA in 2012 to treat metastatic medullary thyroid cancer (56). This evidence concerns the gene NTRK1 and medullary thyroid gland carcinoma.